Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00776087
Other study ID # HS043
Secondary ID
Status Terminated
Phase N/A
First received October 17, 2008
Last updated June 29, 2017
Start date October 17, 2008
Est. completion date October 27, 2016

Study information

Verified date June 2017
Source Biotronik SE & Co. KG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer.

The EuroEco study:

1. Outlines a new HM-based FU model for the ICD and CRT-D patients that combines in-clinic consultations and regular check ups of the patient/ICD/CRT-D data received through the HM service.

2. Compares the direct costs for physicians and clinics for the HM-based FU of ICD and CRT-D patients versus the traditional FU.

3. Compares the indicators of patients' safety between the two FU models.


Description:

The EuroEco is a prospective, international, randomized study aimed at assessing the economic effects of BIOTRONIK Home Monitoring (HM) technology as compared with traditional follow up (FU) of ICD and CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on the physician, hospital and patient. The study outlines a new model for the FU of ICD-and CRT-D patients based on a combination of in-clinic consultations and regular check ups of the patient data received through the HM service.

About 312 patients with an indication for ICD therapy and 104 patients with an indication for de novo CRT-D implantation should be enrolled. All patients will be implanted with BIOTRONIK ICD or CRT-D devices from the Lumax families and randomized (1:1) to the traditional, or to HM-based FU model. Traditional FU will be performed according to the local clinical practice. Patients in the HM study arm will first undergo local clinical FU routine until the first in-clinic visit after patient discharge. Thereafter routine in-clinic FUs are scheduled at 12 and 24 months. Three HM data checks should be carried out during each 12-month interval, to assess the patient/ICD/CRT-D status remotely.

In both (HM and no HM) groups, additional in-hospital FU may be scheduled any time the patients reports symptoms which are presumed to be cardiovascular symptoms. In the HM group, additional in-clinic FU may also be scheduled as a result of specific HM findings.

The following FU-related activities were accounted for: in-clinic consultations, patients contact, discussion with colleague physician, nurse or technician and arranging in clinic consultation. In HM patients, two additional HM-related FU activities were taken into account: 1) checking the website of BIOTRONIK HM Service Center, and 2) checking HM-related emails and faxes (provided by BIOTRONIK HM Service Center)..

Several tools were made available to document the time that physicians, nurses and technicians spend with these FU activities without disrupting their clinical routine much:

- designated case report forms

- a web-based time measurements software.

A user manual for time measurements was handed out to physicians, nurses and technicians to recommend which tool should be used in which clinical situation. The average time per patient followed according to the traditional FU model and the average time per patient followed by the HM-based FU model will be calculated for each of the three health care professionals considered (physicians, nurses and technicians). The difference in costs between the traditional and the HM-based FU will be assessed for statistical significance.

This trial may provide data warranting a change in the guidelines for the use of ICD and CRT-D devices featuring HM function, in that HM may justify a prolongation of the time interval between statutory routine in-clinic FU visits. Coupled with the fact that the information provided by HM helps physicians to recognize some otherwise unsuspected needs for additional FU visits, this may ultimately result in better and more cost-effective health care for all parts involved (patients, providers and payers).


Recruitment information / eligibility

Status Terminated
Enrollment 409
Est. completion date October 27, 2016
Est. primary completion date July 21, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility ICD Patient Population - Inclusion Criteria

- Indication for 1-/2- chamber ICD implantation, including replacement indication

- Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent

ICD Patient Population - Exclusion Criteria

- Patients with contraindication to ICD implantation

- Patients with indication for cardiac resynchronization (CRT)

- Minors and pregnant women

- Patients participating in another study

CRT-D Patient Population - Inclusion Criteria

- Patients with indication for de novo CRT-D implantation according to current guidelines

- Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent

CRT-D Patient Population - Exclusion Criteria

- Patients who had a cardiac device implanted before (upgrade, device replacement)

- Life expectancy less than 12 months

- Planned heart transplantation

- NYHA IV

- Minors < 18 years

- Pregnant and breast-feeding women

- Participation in another clinical study

Study Design


Intervention

Device:
Home Monitoring provided by Biotronik ICD and CRT-D devices
Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
No Home Monitoring
Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).

Locations

Country Name City State
Belgium Heart Rhythm Management Institute, Free University of Brussels Brussels
Belgium Ziekenhuis Oost Limburg, Campus St. Jan Genk
Belgium Jessa Ziekenhuis (Campus Virga Jesse) Hasselt
Belgium ZU Gasthuisberg Leuven
Finland University of Oulu Oulu
Germany Helios Klinikum Aue Aue
Germany Charité Berlin Campus Mitte Berlin
Germany Herzzentrum Leipzig, Abteilung Rhythmologie Leipzig
Germany Städt. Klinikum St. Georg gGmbH Leipzig
Netherlands Leiden Universitair Medisch Centrum Leiden
Spain Hospital Universitario La Paz La Paz
Spain Hospital Universitario Puerta de Hierro Majadahonda Madrid
Spain Hospital Ntra.Sra.de la Candelaria Tenerife
Spain Arrythmia Unit, Complejo Hospitalario de Vigo (Hospital Xeral) Vigo
United Kingdom Cardiology, Aberdeen Royal Infirmary Aberdeen
United Kingdom Cardiology, St. Peters Hospital/St. George's Chertsey
United Kingdom Cardiology; Raigmore Hospital Inverness

Sponsors (1)

Lead Sponsor Collaborator
Biotronik SE & Co. KG

Countries where clinical trial is conducted

Belgium,  Finland,  Germany,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Euro spent to follow up ICD and CRT-D patients 26 months
Secondary Average number of in-hospital follow-up visits per patient 26 months
Secondary Time to first in-hospital follow-up visit beyond the first post-implantation visit 12 months
Secondary Effective financial impact on hospitals / physicians 26 months
Secondary Proportion of in-hospital consultations with relevant findings (i.e. necessitating changes in medical therapy, device programming or re-hospitalisations/ interventions) 26 months
Secondary Proportion of patients with HM-triggered interventions that, without remote monitoring, would have first been discovered at a subsequent scheduled follow-up 26 months
Secondary Incidence of inappropriate ICD shocks 26 months
Secondary Changes in quality-of-life (SF-36) from baseline to the 12- and to 24-month follow-up visits 26 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Active, not recruiting NCT03700125 - Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 ) N/A
Not yet recruiting NCT05325385 - Ventricular Fibrillation Following Out-of-hospital Cardiac Arrest
Completed NCT00139542 - AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute" Phase 3
Completed NCT00241800 - Medications and the Risk of Sudden Cardiac Death N/A
Completed NCT00119847 - Electrophysiological Effects of Late PCI After MI N/A
Completed NCT00004560 - Public Access Defibrillation (PAD) Community Trial Phase 3
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000502 - Evaluation of SC-V Versus Conventional CPR Phase 3
Completed NCT00000492 - Beta-Blocker Heart Attack Trial (BHAT) Phase 3
Completed NCT04080986 - DOuble SEquential External Defibrillation for Refractory VF N/A
Completed NCT01789554 - The Use of Mobile Phones in Out of Hospital Cardiac Arrest to Increase Bystander CPR N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Completed NCT01089634 - Left Ventricular Capture Management Study
Completed NCT00382928 - Automatic External Defibrillation Monitoring in Cardiac Arrest Phase 1
Completed NCT01161589 - First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data N/A
Recruiting NCT04576130 - A Danish ICD-study in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation N/A
Withdrawn NCT05236920 - Utility and Procedural Feasibility of REBOA Operationalized for Non-Trauma Application (UP-FRONT) N/A